Autopsy report · NCT03352414

Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC

“stopped by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 84 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of California, San Diego

Sponsor type

University, hospital or other

Conditions

Ileus

Interventions

Alvimopan; Placebo

Participants

84

Sites

1

Countries

United States

Trials that died the same way

• Target Volume Mode Controlled Ventilator in Obesity Hypoventilation Syndrome
  “Stopped by the sponsor” (98% match in meaning)
• A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
  “Sponsor stopped program\]” (82% match in meaning)
• Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
  “Sponsor chose not to continue” (80% match in meaning)
• TCR Alpha/Beta and CD19-deplete Haplo-HSCT
  “Cancelled by Sponsor” (79% match in meaning)
• SURF, Neurodevelopment, Growth Study in SGA Infants
  “Sponsor decision stopped in June 2017” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.